BioSpace News Archive

Biohaven Ltd. announced preliminary analyses and positive biomarker data from Biohaven’s exploratory Phase 1 electroencephalogram biomarker study, which was presented to epilepsy key opinion leaders at an off-site meeting held during the International Epilepsy Conference 2023 in Dublin, Ireland.

Bicycle Therapeutics (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 12, 2023, at 10:10 a.m. ET.

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at Baird’s 2023 Global Healthcare Conference on Wednesday, Sept. 13, 2023, at 10:15 a.m. Eastern time.

Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies, today announced the closing of an oversubscribed $90 million Series C financing to continue growth of its first-in-class antibody therapies and portfolio companies.

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference in New York, NY on Wednesday, September 13, 2023 at 11:30 a.m. ET.

Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences.

EsoCap AG, the Swiss biotech company dedicated to improving the lives of patients with serious diseases of the upper gastrointestinal tract, reports the completion of patient recruitment in the Phase II ACESO trial.

BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, reported encouraging one-year follow-up data of its breast and pectus excavatum scaffolds.

Heartseed Inc. announced that it has entered into a worldwide non-exclusive patent license agreement with an undisclosed biotech company for its Metabolic Selection technology, a proprietary platform used to selectively remove undifferentiated induced pluripotent stem cells.

Nuvalent, Inc. announced the initiation of the Phase 2 portion of ARROS-1, its Phase 1/2 clinical trial of NVL-520 for patients with ROS1-positive non-small cell lung cancer and other solid tumors, following alignment with the US Food and Drug Administration on a recommended Phase 2 dose of 100 mg daily.